Novel multimodal model leverages ctDNA and imaging features for risk stratification in NSCLC patients, suggesting potential for adaptive therapy.
Summary: This spotlight highlights a novel multimodal risk stratification model for patients with locally advanced non–small cell lung cancer undergoing chemoradiation, integrating mid-treatment ctDNA kinetics with radiomic features from baseline imaging. The study by Moding and colleagues provides compelling proof-of-concept data for real-time response-adaptive therapy, though further work is needed to address implementation barriers and standardize these biomarkers for clinical use. See related article by Moding et al., p. 1609
No takes yet. Share an insight, caveat, or question.
Anagnostou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: